The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: Effects of vitamin status

Clinical Neuropharmacology

Volumn 29, Issue 3, 2006, Pages 106-111

  Zesiewicz, Theresa A ^a,b   Wecker, Lynn ^a   Sullivan, Kelly L ^a,b   Merlin, Lisa R ^c   Hauser, Robert A ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

B 12; COMT inhibitors; Entacapone; Folate; Homocysteine; Parkinson disease; Vitamins

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; CYANOCOBALAMIN; ENTACAPONE; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; CATECHOL DERIVATIVE; CATECHOL METHYLTRANSFERASE; VITAMIN;

ARTICLE; COMPARATIVE STUDY; DATA BASE; DIET RESTRICTION; DRUG EFFICACY; ENZYME INHIBITION; FOLIC ACID BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; MONOTHERAPY; PARKINSON DISEASE; PRIORITY JOURNAL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG COMBINATION; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

CATECHOL O-METHYLTRANSFERASE; CATECHOLS; DRUG THERAPY, COMBINATION; FOLIC ACID; HOMOCYSTEINE; HUMANS; LEVODOPA; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS; VITAMIN B 12; VITAMINS;

EID: 33746444443     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.WNF.0000220817.94102.95     Document Type: Article

References (21)

1. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk August 1998;5(4):229-232.
2. Refsum H, Ueland PM, Nygard O, et al. Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31-42.
3. Stabler SP, Marcell PD, Podell ER, et al. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest February 1988;81(2):466-474.
4. Medina M, Urdiales JL, Amores-Sanchez MI. Roles of homocysteine in cell metabolism: old and new functions. Eur J Biochem July 2001;268(14):3871-3872.
5. Selhub J, Jacques PF, Wilson PWF, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-2698.
6. Allain P, Le Bouil A, Cordillet E, et al. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology Fall 1995;16(3):527-529.
7. Kuhn W, Roebroek R, Blom H, Van Oppenraaij D, et al. Hyperhomocysteinaemia in Parkinson's disease. J Neurol December 1998;245(12):811-812.
8. Muller T, Werne B, Fowler B, et al. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet July 10, 1999;354(9173):126-127.
9. Rogers JD, Sanchez-Saffon A, Frol AB, et al. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol January 2003;60(1):59-64.
10. Lamberti P, Zoccolella S, Iliceto G, et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov Disord 2005;20:69-72.
11. Zoccolella S, Lamberti P, Armenise E, et al. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Parkinsonism Relat Disord 2005;11:131-133.
12. Valkovic P, Benetin J, Blazicek P, et al. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism Relat Disord 2005;11:253-256.
13. Ostrem JL, Kand GA, Subramanian I, et al. The effect of entacapone on homocysteine levels in Parkinson disease. Neurology April 26, 2005;64(8):1482.
14. O'Suilleabhain PE, Bottglieri T, RB Dewey Jr, et al. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's Disease. Mov Disord 2004;19(12):1403-1408.
15. Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med May 13, 1999;340(19):1449-1454.
16. Lamberti P, Zoccolella S, Armenise E, et al. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. Eur J Neurol 2005;12(5):365-368.
17. Lavie L, Lavie P. Daily rhythms in plasma levels of homocysteine. J Circadian Rhythms 2004;2:1-6.
18. Ubbinnk JB, Vermaak WJH, et al. The effect of blood sample aging and food consumption on plasma total homocysteine levels. Clin Chim Acta 1992;207:119-128.
19. Nurk E, Tell GS, Nygard O, et al. Plasma total homocysteine is influenced by prandial status in humans: the Hordaland Homocysteine Study. J Nutr 2001;131:1214-1216.
20. Duell PB, Malinow MR, Gregory JF, et al. Reduction of fasting and postprandial plasma homocysteine levels by a semivegetarian very low-fat diet. Circulation 1998;98:192. [abs].
21. Van der Griend R, Haas FJ, Duran M, et al. Methionine loading test is necessary for detection of hyperhomocysteinemia. J Lab Clin Med 1998;132:67-72.